Drug Profile
CGX 1007
Alternative Names: Con-G; Conantokin GLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Salk Institute; University of Utah
- Developer Cognetix
- Class Antiepileptic drugs; Neuroprotectants
- Mechanism of Action NR2B N-Methyl-D-Aspartate antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Epilepsy; Neurodegenerative disorders; Pain
Most Recent Events
- 26 Oct 2005 Discontinued - Phase-I for Neurodegenerative disorders in USA (IV)
- 26 Oct 2004 CGX 1007 is available for licensing (http://www.cognetix.com)
- 26 Oct 2004 Discontinued - Phase-I for Epilepsy in USA (Intrathecal)